0001171843-18-001103.txt : 20180213
0001171843-18-001103.hdr.sgml : 20180213
20180213164823
ACCESSION NUMBER: 0001171843-18-001103
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180213
FILED AS OF DATE: 20180213
DATE AS OF CHANGE: 20180213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lichtlen Peter
CENTRAL INDEX KEY: 0001636644
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33609
FILM NUMBER: 18604244
MAIL ADDRESS:
STREET 1: 4520 EAST WEST HIGHWAY, 3RD FLOOR
CITY: BETHESDA
STATE: MD
ZIP: 20814
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sucampo Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001365216
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133929237
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 805 KING FARM BOULEVARD, SUITE 550
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 3019613400
MAIL ADDRESS:
STREET 1: 805 KING FARM BOULEVARD, SUITE 550
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
4
1
f4_lichtlen021318.xml
OWNERSHIP DOCUMENT
X0306
4
2018-02-13
1
0001365216
Sucampo Pharmaceuticals, Inc.
SCMP
0001636644
Lichtlen Peter
805 KING FARM BLVD, SUITE 550
ROCKVILLE
MD
20850
0
1
0
0
Chief Medical Officer
Common Stock, Class A
2018-02-13
4
D
0
24000
18.00
D
0
D
Stock Option (right to buy)
4.27
2018-02-13
4
D
0
78200
13.73
D
2021-06-01
Common Stock
78200
0
D
Stock Option (right to buy)
7.17
2018-02-13
4
D
0
78200
10.83
D
2024-07-01
Common Stock
78200
0
D
Stock Option (right to buy)
6.75
2018-02-13
4
D
0
25000
11.25
D
2024-09-11
Common Stock
25000
0
D
Stock Option (right to buy)
14.82
2018-02-13
4
D
0
44000
3.18
D
2025-03-04
Common Stock
44000
0
D
Stock Option (right to buy)
13.80
2018-02-13
4
D
0
44000
4.20
D
2026-03-02
Common Stock
44000
0
D
Stock Option (right to buy)
11.85
2018-02-13
4
D
0
45000
6.15
D
2027-03-02
Common Stock
45000
0
D
This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of restricted stock units that were accelerated as a result of the Merger Agreement.
This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
/s/ Peter Lichtlen
2018-02-13